Missouri Marijuana Operators Still Await IRS Guidance After Rescheduling

Missouri operators have the reclassification but not the tax answer

Missouri's medical marijuana businesses celebrated April's federal reclassification, but they still lack the IRS direction that would turn it into lower tax bills.

Reporter Rebecca Rivas of the Missouri Independent wrote that Missouri marijuana businesses had reason to celebrate in April, when federal officials moved medical marijuana into a less restrictive category. Marijuana Moment republished the report on Oct. 31, 2026.

The mood since then is less festive. Operators are described as "very anxious" to learn whether relief is coming and whether the IRS will issue guidance spelling out what they can do.

Not yet. The reporting as published doesn't cite a release date for that guidance.

Why 280E makes a drug schedule into a tax bill

Section 280E of the Internal Revenue Code ties a business's deductions to the federal schedule of the substance it sells.

The statute, in force since 1982, bars deductions and credits for any business trafficking in Schedule I or II controlled substances. Marijuana operators have lived under it for decades. In practice they can subtract little beyond cost of goods sold, so a business can post an accounting profit that looks nothing like its taxable income.

A reclassification matters because the statute's text reaches only those two schedules. If the new classification sits outside Schedules I and II, the legal argument for ending 280E treatment gets much stronger. But a statute doesn't administer itself. The IRS decides how returns get filed, audited and amended, and that's why operators are watching Washington's tax agency rather than its drug regulators.

One wrinkle stands out. The report describes the April action as covering medical marijuana. Missouri licenses both medical and adult-use sellers, so a lot depends on how the IRS treats each revenue stream.

The questions guidance would have to settle

Operators can't plan cash, pricing or expansion until the IRS answers a short list of practical questions.

These are our read of what the guidance would need to cover, not a list from the Missouri Independent:

• Effective date. Does 280E stop applying from the April action, from a later date, or only for tax years that begin after guidance issues?
• Mixed revenue. How should a company selling both medical and adult-use product allocate costs and deductions between the two?
• Prior years. Can operators amend earlier returns, or is any relief strictly forward-looking?
• Audit posture. What happens to open examinations built on 280E positions?

Each answer moves real money. For a vertically integrated Missouri licensee, the gap between a 280E return and an ordinary return can decide whether a quarter is profitable. Estimated tax payments and lender covenants hang on the same unresolved line, and so do expansion budgets.

For full background on this story, see the CannIntel topic hub on 280E tax relief after rescheduling.

How other regimes avoid the problem Washington created

Few other legal markets attach a tax penalty to a drug classification, which is why the U.S. fix runs through the IRS rather than a regulator.

Germany's BfArM oversees medical cannabis, and since April 2024 that program has run under the Medical Cannabis Act (MedCanG) rather than the Narcotics Act. Canada's Health Canada licenses producers under the Cannabis Act and collects a federal excise duty on product. In both systems the tax burden attaches to the product or the profit, not to a denial of normal business deductions.

The U.S. problem is self-inflicted. It's a tax penalty bolted to a drug schedule. It also explains why a domestic schedule change, which keeps marijuana a controlled substance, can reshape tax liability without touching the international drug-control framework the INCB monitors. A lower U.S. schedule is a fix Washington can make alone, but it only works if the IRS follows through.

That leaves Missouri operators in an awkward spot, with a regulatory win on paper and a tax return that still has to be filed under old assumptions while the guidance they need hasn't arrived.

Watch for one thing next: whether the IRS or Treasury issues written guidance on 280E treatment for medical marijuana, and whether it addresses the adult-use revenue sitting next to it.